Dose Escalation by Boosting Radiation Dose in Stage II and III Non Small Cell Lung Cancer (NSCLC): a Phase II Trial

2014-08-27 03:17:33 | BioPortfolio


Increasing ("boosting") the radiation dose for patients with non-small cell lung carcinoma to the individual maximal dose which can safely be given. The question is if patients should receive this boost on the whole tumor on part of the tumor. Therefore patients are randomized for one of these two treatment options. All patients will receive 24 radiations. Dose increasement will be enabled by a so called integrated boost.


Background Increasing the radiation dose can lead to better results. Using IMRT it is possible to make inhomogeneous dosisdivisions so a part of the radiation area can receive a higher dose. IMRT is being used as a standard for some years in patients which are being radiated for lung carcinoma.

Recent investigations show that the primary tumor in the lung is the place

where lung cancer recur most frequently and much less in the lymph glands in the mediastinum. From the part of the primary tumor with the highest activity on the PET-scan* (Positron Emission Tomography) the chance that de cancer recurs is higher than in the part of the tumor that shows low or no activity on the PET.

Because it is not clear if the organs in the area between the lungs can bare a higher radiation dose safely, we ensure that these vulnerable organs receive a radiation dose of which we are sure it is safe.

Aim of the investigation We would like to increase ("boost") the radiation dose for patients with non-small cell lung carcinoma to the individual maximal feasable dose which, according to the normal tissue tolerance models, can be given safely. The question is on which area we can best increase the radiation dose. Therefore we randomize a group of patients between a boost on the whole tumor and a group patients that receive a boost on part of the lung tumor. The area that receives the higher dose will be assigned by lot. All patients will be radiated 24 times. The dose increasement takes place by a so called integrated boost.

Population Patients with a non-small cell inoperable lung carcinoma, stage I and II which will be treated with chemotherapy and radiotherapy or radiotherapy alone and have signed the consent form.

All patients must have received a complete radiotherapy planning before the randomisation in order to see if a higher dose can be given safely.

Study Design

Allocation: Randomized, Control: Dose Comparison, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment






MAASTRO clinic
6229 ET




Maastricht Radiation Oncology

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:17:33-0400

Clinical Trials [513 Associated Clinical Trials listed on BioPortfolio]

BreAst Cancer and Cardiotoxicity Induced by RAdioTherapy: the BACCARAT Study

Breast radiotherapy RT used until the 1990s was clearly responsible for increased mortality due to long term cardiac complications. Since the 2000s, improvements have appeared in dose dist...

Clinical Impact of EUS in Staging NSCLC

The goal of this prospective study is to determine the clinical and economic impact of endoscopic ultrasound (EUS) in staging NSCLC. Aims: 1) Determine the accuracy of EUS in staging NSCL...

Iressa as Second Line Therapy in Advanced NSCLC-Asia

This is a randomized, open-label, parallel group, phase III, multicenter, regional study. The total number of patients expected to be exposed to study procedures is approximately 150 patie...

Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients

The purpose of this study is to determine if the combination of Taxotere and exisulind is an effective and safe treatment for patients with advanced NSCLC who have failed a prior platinum-...

Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer

This is a Phase II, open-label, 4-cohort study of the monoclonal antibody BGB A317 in combination with standard platinum-based chemotherapy in subjects with advanced NSCLC or SCLC. The 4 c...

PubMed Articles [1375 Associated PubMed Articles listed on BioPortfolio]

Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience.

To investigate the role of conventional radiotherapy (RT) and stereotactic body radiotherapy (SBRT) in patients with epidermal growth factor (EGFR)-mutant or anaplastic lymphoma kinase (ALK) rearrange...

Nomograms for predicting disease progression in patients of Stage I non-small cell lung cancer treated with stereotactic body radiotherapy.

Non-local progression is a major concern in non-small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy (SBRT). Herein we aimed to create a pre-treatment prognostic nomogram for pat...

Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms.

Despite the unheralded success of immune checkpoint blockade in delivering durable responses for some patients with non-small cell lung cancer (NSCLC), the majority of patients do not respond. PD-L1 t...

An overview on personalisation of radiotherapy prescriptions in locally advanced non-small cell lung cancer: Are we there yet?

Standard of care radiotherapy in LA-NSCLC is 60-66 Gy in 30-33 fractions. However outcomes for these patients are poor with 5-year survival in the range of 10-20%. Randomised controlled trials have ...

Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients: Efficacy and Safety of Combination.

In the last decade, the discovery of immune checkpoint inhibitors such as the PD-1 inhibitor, nivolumab, has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). Concurrent rad...

Medical and Biotech [MESH] Definitions

Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.

The total amount of radiation absorbed by tissues as a result of radiotherapy.

Radiotherapy where there is improved dose homogeneity within the tumor and reduced dosage to uninvolved structures. The precise shaping of dose distribution is achieved via the use of computer-controlled multileaf collimators.

Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).

Computer-assisted mathematical calculations of beam angles, intensities of radiation, and duration of irradiation in radiotherapy.

More From BioPortfolio on "Dose Escalation by Boosting Radiation Dose in Stage II and III Non Small Cell Lung Cancer (NSCLC): a Phase II Trial"

Quick Search


Relevant Topics

Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Searches Linking to this Trial